Arizona Bioscience Overview:
Arizona Pioneer Thomas M. Grogan, MD:
Dr. Grogan was a pathologist and professor at the University of Arizona when in the mid 1980’s he and a small team set out to challenge the limitations of the then current standards and processes for cancer pathology. What was to become the company’s first digital pathology instrument evolved from Grogan’s notes on a yellow pad into the BenchMark IHC/ISH staining platforms. Under Grogan’s leadership, Ventana was founded in 1987, went public in 1996, and was acquired by Roche for $3.4 billion in 2008. Over the last 25 years, Ventana has grown to become a global leader in developing and manufacturing tissue-based diagnostic instruments and tests focused on the detection of cancer. Ventana employees continue to pursue the same deeply rooted mission of innovating diagnostic testing and enabling personalized healthcare to improve the lives of all patients afflicted with cancer worldwide.
Dr. Grogan has made it his personal mission to make life better for the millions of patients who battle cancer each day. His passion and dedication are infectious and has spread across the company that he and his team built. Through their efforts they have revolutionized the field of cancer diagnostics and are pioneering new roads in the field of personalized healthcare.”
Leslie Boyer, MD 2013 Arizona Bioscience Researcher of the Year:
Linda Hunt of Dignity Health Arizona, 2013 Arizona Bioscience Leader of the Year:
Recognizing that collaboration builds a stronger community, Linda Hunt has taken a leadership role to advance healthcare and the biosciences for the people of Arizona. Hunt has worked diligently with legislators, business leaders, educators, scientists and community organizations in order to identify, formulate, and support policies that will give Arizonans better healthcare and raise the bar of knowledge.Hunt has served as the head of Dignity Health in Arizona since 2012. Dignity Health includes three major hospitals in the Valley, St. Joseph’s Hospital and Medical Center and Chandler Regional and Mercy Gilbert Medical Centers. A fourth hospital, St. Joseph’s Westgate, is under construction.
An Extra 30 Years – Joan Koerber-Walker, AZBio (2019)
In the healthcare discussion, as we look at the value of
life science innovations, we must never forget the importance of the years.
Joan Koerber-Walker, president and CEO of the Arizona
Bioindustry Association (AZBio), leads an organization representing companies
who together employ over 300,000 Arizonans who are discovering, developing, and
delivering life science innovations that make life better in Arizona, across
the United States, and around the world.
2019 AZBio Fast Lane Award Honoree - OncoMyx Therapeutics
National Cancer Institute (NCI) estimates that there will be over 600,000
deaths from cancer in 2019. That is
roughly two percent of the U.S population.
The majority of these deaths will be caused by cancers that form
into solid tumors.
OncoMyx, a startup launched from Arizona State University (ASU), develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have emerged as a safe and effective immuno-oncology complement. The company’s MYXV platform is poised to be a best-in-class oncolytic virus approach, and the top oncolytic virus team has assembled around MYXV to create important new therapeutic options for cancer patients. OncoMyx is currently being launched in Phoenix to test next-generation viruses in human clinical trials against a variety of human cancers.
2019 AZBio Fast Lane Award Honoree - GT Medical Technologies
400,000 Americans are newly diagnosed with some type of brain tumor each
year. For decades, clinicians have sought better treatments for these
patients that would effectively target tumor cells while preserving
healthy tissue, but to no avail. There have been few new effective
therapies over the past 30 years, and outcomes for patients have improved
very little during this time. Recurrence of brain tumors is common, and
about half of all patients treated for brain tumors have their disease
recur within a year. As a result, patients often run out of treatment
options when their tumors reoccur. GT MedTech is a medical technology
company passionately committed to improving the lives of patients with
brain tumors. This company is an excellent example of how the combination
of leading edge research and development combined with an experienced
management team can move a company forward faster.
2019 AZBio Fast Lane Award Honoree - Biosensing Instrument
a new drug is one of the most expensive and complex innovation challenges.
Biosensing Instrument, Inc. (BI), a Tempe based life science company, is
transforming early drug discovery research at pharmaceuticals and academic
laboratories around the world by enabling measurements that were not
The Entrepreneurial Journey – James Bates, AdviNow Medical (2019)
James Bates, CEO of AdviNow Medical, shares insights on the
entrepreneurial journey at the 2019 AZBio Awards